Trending

Crohn’s disease

Takeda finalises buyout of TiGenix

Takeda finalises buyout of TiGenix

Japanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology

X

Takeda finalises buyout of TiGenix

https://pharmaphorum.com/news/japanese-takeda-finalises-tigenix-boyout/

Pioneering Crohn’s antibiotic treatment meets early target

Pioneering Crohn’s antibiotic treatment meets early target

A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial.

X

Pioneering Crohn’s antibiotic treatment meets early target

https://pharmaphorum.com/news/pioneering-crohns-antibiotic-treatment-meets-early-target/

First ever ‘off the shelf’ stem cell therapy nears European approval

First ever ‘off the shelf’ stem cell therapy nears European approval

Alofisel recommended for complex perianal fistulas in Crohn’s disease

X

First ever ‘off the shelf’ stem cell therapy nears European approval

https://pharmaphorum.com/news/tigenixtakeda-stem-cell-therapy-backed-eu-regulators/

Janssen inks potential $1bn deal for IBD drug

Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in

X

Janssen inks potential $1bn deal for IBD drug

https://pharmaphorum.com/news/janssen-inks-potential-1bn-deal-ibd-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com